查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球鱗狀細胞癌市場-2022-2029
市場調查報告書
商品編碼
1129239

全球鱗狀細胞癌市場-2022-2029

Global Cutaneous Squamous Cell Carcinoma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

鱗狀細胞癌非侵入性診斷技術的增加預計將推動市場增長。

晚期 cSCC 的診斷涉及多學科專家，包括皮膚科醫師、解剖病理學家、外科醫生、放射腫瘤科醫師和內科腫瘤科醫師，可以對患者進行更全面的評估。非侵入性光學診斷技術越來越多地用於臨床環境中，以提高診斷準確性並在手術或活檢之前對體內腫瘤進行表徵。 cSCC 的主要特徵，例如聚集的血管模式、腎小球血管和角化過度，可以通過皮膚鏡檢查確認。反射共聚焦顯微鏡顯示表皮棘狀顆粒層異常蜂窩狀和無序圖案、表皮圓形有核明亮細胞和圓形真皮靜脈。此外，皮膚鏡檢查更常用於色素性病變而不是非色素性病變，用於對不明確病例的鑑別診斷。因此，上述描述有望推動市場的增長。

限制

在預測期內，治療成本上升、治療成本無法報銷、並發症增加以及疾病早期發現不足被認為是阻礙市場發展的因素。

行業分析

鱗狀細胞癌市場根據波特五力、供應鏈分析、報銷方案、管道分析、產品創新和定價分析等各種行業因素對市場進行深入分析。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。由於封鎖，對流行病的醫療和外科手術干預已被推遲。此外，沒有感染新冠病毒的患者的非緊急醫療就診被取消或推遲，人們因害怕感染病毒並進一步加重系統壓力而不願聯繫衛生服務機構。因此，全球癌症診斷率有所下降，尤其是皮膚惡性腫瘤。例如，荷蘭的一項研究發現，從 2 月底到 2020 年 4 月初，所有惡性腫瘤的每週癌症診斷率下降了 27%，皮膚癌的診斷率下降了 61%。

此外，大流行還會擾亂供應鍊和流程。許多公司將轉移到其他地區以確保產品可用性並保護其供應鏈。因此，從上述陳述來看，市場受到了影響，但隨著經濟活動的恢復，預計將迅速獲得牽引力。

全球鱗狀細胞癌市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 鱗狀細胞癌無創診斷技術的興起有望推動市場增長。
    • 限制因素
      • 在預測期內，飆升的治療成本預計將成為抑制因素。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章診斷領域

  • CT
  • 核磁共振
  • 活檢
  • 其他

第 8 章按治療類型

  • 手術治療
    • 莫氏顯微手術 (MMS)
    • 刮宮術/電極燒灼術
    • 切除手術
    • 冷凍手術
    • 激光手術
    • 其他
  • 非手術治療
    • 免疫反應改善劑（外用
      • 咪奎莫特
      • 要求
    • 化療
    • 藥物治療
      • Keytruda（派姆單抗）
      • Ribtaiyo (semiprolimab)
      • 其他
    • 放射治療
    • 光動力療法 (PDT)
    • 全身化療
    • 其他
  • 其他

第 9 章按治療方法銷售

  • 最終用戶
    • 醫院
    • 門診手術中心
    • 診斷中心
    • 其他
  • 銷售渠道
    • 醫院藥房
    • 零售藥房
    • 在線藥店
    • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • Regeneron Pharmaceuticals, Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Sanofi
  • Merck & Co., Inc.
  • Mayne Pharma Group Limited
  • iNova Pharmaceuticals
  • Bristol-Myers Squibb Company
  • LGM PHARMA
  • Hikma Pharmaceuticals PLC
  • 3M Health Care Limited

第 13 章全球鱗狀細胞癌市場-DataM

簡介目錄
Product Code: DMPH5778

Market Overview

Cutaneous Squamous Cell Carcinoma Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 7.2 % during the forecast period (2022-2029).

Cancer starts in the cells that make up the epidermis (the outer layer of the skin). It commonly develops in parts of the skin that have been exposed to long periods of natural or artificial sunlight (such as from tanning beds). The face, ears, lower lip, neck, arms, and backs of the hands are examples of these locations. It can also happen if you've had your skin burned or exposed to chemicals or radiation. A hard red bump, a scaly red patch, an open sore, or a wart that crusts or bleeds easily can all be signs of cutaneous squamous cell carcinoma. Squamous cell carcinoma of the skin that hasn't spread can typically be cured.

Market Dynamics

Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.

Diagnosis of advanced cSCC involves experts from different specialties, including dermatologists, anatomical pathologists, surgeons, radiation oncologists, and medical oncologists, thereby enabling a more comprehensive patient assessment. Noninvasive optical diagnostic techniques are increasingly used in clinical practice to increase diagnostic accuracy and characterize tumors in vivo before surgery or biopsy. The primary characteristics of cSCC, such as clustered vascular patterns, glomerular vessels, and hyperkeratosis, can be identified through dermoscopy. Reflectance confocal microscopy can reveal aberrant honeycomb or disorganized patterns in the epidermis' spinous-granular layer, round nucleated brilliant cells in the epidermis, and round dermis veins things. Moreover, dermoscopy is used more commonly in pigmented lesions than in non-pigmented lesions in the differential diagnosis of equivocal cases. Thus, from the above statements, the market is expected to drive market growth.

Restraint:

The high cost of the treatment, lack of reimbursement for the treatment, increase in complications rate, and lack of early detection of the diseases are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cutaneous squamous cell carcinoma market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, pipeline analysis, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Medical and surgical operations for prevalent ailments have been delayed due to the lockdown. Moreover, Non-COVID patients had non-urgent medical visits canceled or postponed, and people were hesitant to contact healthcare services for fear of getting the virus and burdening the system further. This has resulted in a decrease in cancer diagnoses worldwide, particularly in skin malignancies. For instance, a Dutch study found a decline in weekly cancer diagnoses of up to 27% for all malignancies and 61% for skin cancers between the end of February and the beginning of April 2020.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Surgical segment is expected to hold the largest market share in cutaneous squamous cell carcinoma market

The surgical segment is expected to dominate in 2021. Most squamous cell carcinomas of the skin can be eliminated with minimal surgery or, on rare occasions, with a topical medication. The size, location, and aggressiveness of the tumor matter. For instance, Based on excellent cure rates and low recurrence rates reported in retrospective assessments of initial and recurrent cSCC, Mohs micrographic surgery (MMS) might be the best approach for high-risk patients. Moreover, if skin cancer is very small and has a low risk of spreading, less invasive treatments are the treatment choice. For instance, Curettage and electrodessication (C and E) treatment involves removing the skin cancer surface with a scraping instrument (curet) and then searing the base of the cancer with an electric needle. This treatment is often used for small or very superficial squamous cell skin cancers. Therefore, there is an increase in the demand for surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global cutaneous squamous cell carcinoma market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cutaneous squamous cell carcinoma, advancements in the treatment, well-established infrastructure and product launches and collaborations by the key players are some factors the market is expected to boost in the forecast period. For instance, Cutaneous squamous cell carcinoma (CSCC, also called squamous cell carcinoma of the skin) is the second most common form of skin cancer and five times more prevalent than melanoma in the U.S. Moreover, according to the American Cancer Society, Of nonmelanoma skin cancers, approximately 80% are basal cell carcinoma (BCC), and 20% are squamous cell carcinoma (SCC). In addition, Regeneron Pharmaceuticals, Inc. announced its intention to buy Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab) on June 2, 2022 giving Regeneron exclusive global development, commercialization, and manufacturing rights to the medicine.

Furthermore, Merck & Co., Inc. received FDA approval for pembrolizumab (KEYTRUDA) in June 2020. The drug is approved to treat recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) resistant to surgery or radiation. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the cutaneous squamous cell carcinoma market are Regeneron Pharmaceuticals, Inc., Sanofi, Merck & Co., Inc., Mayne Pharma Group Limited, iNova Pharmaceuticals, Bristol-Myers Squibb Company, LGM PHARMA, Hikma Pharmaceuticals PLC, 3M Health Care Limited

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology business based in New York's Westchester County. The business was established in 1988. The company began by studying neurotrophic factors, and their regenerative abilities, hence its name, and subsequently expanded to include cytokine and tyrosine kinase receptor research. Currently, the company engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

LIBTAYO (cemiplimab-rwlc) injection: LIBTAYO is indicated for treating patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

The global cutaneous squamous cell carcinoma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high costs of treatment are expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 7.2. CT
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. MRI
  • 7.4. Biopsy
  • 7.5. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Surgical*
    • 8.2.1. Moh's Micrographic Surgery (MMS)
    • 8.2.2. Curettage and electrodesiccation
    • 8.2.3. Excisional surgery
    • 8.2.4. Cryosurgery
    • 8.2.5. Laser surgery
    • 8.2.6. Others
    • 8.2.7. Introduction
    • 8.2.8. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Non-surgical
    • 8.3.1. Topical Immune Response Modifiers
      • 8.3.1.1 Imiquimod
      • 8.3.2.1Resiquimod
    • 8.3.2. Chemotherapy
    • 8.3.3. Medications
      • 8.3.3.1 Keytruda (Pembrolizumab)
      • 8.3.3.2 Libtayo (Cemiplimab-rwlc)
      • 8.3.3.3 Others
    • 8.3.4. Radiotherapy
    • 8.3.5. Photodynamic therapy (PDT)
    • 8.3.6. Systemic Chemotherapy
    • 8.3.7. Others
  • 8.4. Others

9. By Treatment Sales

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 9.1.2. Market Attractiveness Index, By Treatment Sales Segment
  • 9.2. End user*
    • 9.2.1. Hospitals
    • 9.2.2. Ambulatory Surgical Center
    • 9.2.3. Diagnostic Centers
    • 9.2.4. Others
    • 9.2.5. Introduction
    • 9.2.6. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Regeneron Pharmaceuticals, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi
  • 12.3. Merck & Co., Inc.
  • 12.4. Mayne Pharma Group Limited
  • 12.5. iNova Pharmaceuticals
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. LGM PHARMA
  • 12.8. Hikma Pharmaceuticals PLC
  • 12.9. 3M Health Care Limited

LIST NOT EXHAUSTIVE

13. Global Cutaneous Squamous Cell Carcinoma Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us